Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | THPO | P40225 | 2/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.51 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7472261 | 0.85 | CYP4F2 (0.62) | CYP4F2CYP4A11LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL7466474 | 0.84 | LMNA (0.60) | LMNAALDH1A1SMN1; SMN2MAPTHIF1A | |
| SCHEMBL12102434 | 0.84 | EGFR (0.49) | LMNAALDH1A1SMN1; SMN2MAPTHIF1A | |
| SCHEMBL15226692 | 0.82 | HIF1A (0.69) | LMNAALDH1A1SMN1; SMN2MAPTHIF1A | |
| Chlorphenacyl SCHEMBL7468547 | 0.80 | LMNA (0.66) | LMNAALDH1A1SMN1; SMN2MAPTHIF1A | |
| SCHEMBL7472387 | 0.80 | ALDH1A1 (0.57) | LMNAALDH1A1SMN1; SMN2MAPTHIF1A | |
| SCHEMBL6595162 | 0.79 | EGFR (0.53) | LMNAALDH1A1SMN1; SMN2MAPTHIF1A | |
| SCHEMBL12102420 | 0.79 | HDAC6 (0.68) | LMNAALDH1A1SMN1; SMN2MAPTHIF1A | |
| SCHEMBL14383970 | 0.79 | CYP3A4 (0.59) | LMNAALDH1A1SMN1; SMN2MAPTHIF1A | |
| SCHEMBL4113212 | 0.78 | CYP4F2 (0.76) | CYP4F2CYP4A11LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760860-B1 | NITROGEN MUSTARD DERIVATIVES | EURO CELTIQUE SA (LU) | 2016-11-16 | — | — | EP | disclosed |
| EP-2760860-B1 | NITROGEN MUSTARD DERIVATIVES | EURO CELTIQUE SA (LU) | 2016-11-16 | — | — | EP | disclosed |
| US-8962855-B2 | Nitrogen mustard derivatives | PURDUE PHARMACEUTICAL PRODUCTS, L.P. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962855-B2 | Nitrogen mustard derivatives | PURDUE PHARMACEUTICAL PRODUCTS, L.P. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962855-B2 | Nitrogen mustard derivatives | PURDUE PHARMACEUTICAL PRODUCTS, L.P. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140303218-A1 | Nitrogen Mustard Derivatives | NORTHLAKE INTERNATIONAL LLC | 2014-10-09 | — | — | US | disclosed |
| US-20140303218-A1 | Nitrogen Mustard Derivatives | NORTHLAKE INTERNATIONAL LLC | 2014-10-09 | — | — | US | disclosed |
| US-20140303218-A1 | Nitrogen Mustard Derivatives | NORTHLAKE INTERNATIONAL LLC | 2014-10-09 | — | — | US | disclosed |
| EP-2760860-A2 | NITROGEN MUSTARD DERIVATIVES | Euro-Celtique S.A. (LU) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049279-A2 | NITROGEN MUSTARD DERIVATIVES | CRYSTAL BIOPHARMACEUTICALS LLC (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049279-A2 | NITROGEN MUSTARD DERIVATIVES | CRYSTAL BIOPHARMACEUTICALS LLC (US) | 2013-04-04 | — | — | WO | disclosed |
| EP-0711768-B1 | BENZIMIDAZOLE DERIVATIVE | MITSUI CHEMICALS INC (JP) | 2002-02-13 | — | — | EP | disclosed |
| US-5852011-A | Benzimidazole derivatives | MITSUI CHEMICALS, INC. (JP) | 1998-12-22 | — | — | US | disclosed |
| EP-0711768-A1 | BENZIMIDAZOLE DERIVATIVE | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303218-A1 | Nitrogen Mustard Derivatives | IFNG, HNMT, IFNAR1 | CYP4F2 1454/4885CYP4A11 1478/4885LMNA 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.